Effects of ambroxol on the autophagy-lysosome pathway and mitochondria in primary cortical neurons

J. Magalhaes,M. E. Gegg,A. Migdalska-Richards,A. H. Schapira

DOI: https://doi.org/10.1038/s41598-018-19479-8

IF: 4.6

2018-01-23

Scientific Reports

Abstract:Glucocerebrosidase (GBA1) mutations are the major genetic risk factor for Parkinson’s Disease (PD). The pathogenic mechanism is still unclear, but alterations in lysosomal-autophagy processes are implicated due to reduction of mutated glucocerebrosidase (GCase) in lysosomes. Wild-type GCase activity is also decreased in sporadic PD brains. Small molecule chaperones that increase lysosomal GCase activity have potential to be disease-modifying therapies for GBA1-associated and sporadic PD. Therefore we have used mouse cortical neurons to explore the effects of the chaperone ambroxol. This chaperone increased wild-type GCase mRNA, protein levels and activity, as well as increasing other lysosomal enzymes and LIMP2, the GCase transporter. Transcription factor EB (TFEB), the master regulator of the CLEAR pathway involved in lysosomal biogenesis was also increased upon ambroxol treatment. Moreover, we found macroautophagy flux blocked and exocytosis increased in neurons treated with ambroxol. We suggest that ambroxol is blocking autophagy and driving cargo towards the secretory pathway. Mitochondria content was also found to be increased by ambroxol via peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC1-α). Our data suggest that ambroxol, besides being a GCase chaperone, also acts on other pathways, such as mitochondria, lysosomal biogenesis, and the secretory pathway.

multidisciplinary sciences

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to explore the effects of Ambroxol on the autophagy - lysosome pathway and mitochondria in primary cortical neurons. Specifically, the study aims to verify whether Ambroxol can improve Parkinson's disease (PD) - related symptoms, especially PD related to GBA1 gene mutations, by increasing the activity of wild - type glucocerebrosidase (GCase). In addition, the study also explores the effects of Ambroxol on lysosome biogenesis, the autophagy pathway and the secretory pathway, as well as its effects on α - synuclein metabolism and exocytosis. ### Main research questions: 1. **The effect of Ambroxol on GCase activity**: Study whether Ambroxol can increase the mRNA, protein levels and activity of wild - type GCase. 2. **The effect of Ambroxol on lysosome biogenesis**: Evaluate whether Ambroxol can increase the levels of other lysosomal enzymes and LIMP2 (GCase transporter) and activate transcription factor EB (TFEB), which is the master regulator of lysosome biogenesis. 3. **The effect of Ambroxol on the autophagy pathway**: Analyze whether Ambroxol will affect the autophagy flux, especially the level changes of LC3B - II and P62/SQSTM1. 4. **The effect of Ambroxol on mitochondria**: Study whether Ambroxol can increase mitochondrial content by activating PGC1 - α. 5. **The effect of Ambroxol on α - synuclein metabolism**: Evaluate whether Ambroxol can reduce the intracellular level of phosphorylated α - synuclein and increase the exocytosis of α - synuclein. 6. **The effect of Ambroxol on Gba1 - deficient neurons**: Study the role of Ambroxol in Gba1 knockout and heterozygous neurons to determine whether its effect depends on the expression and activity of GCase. ### Research background: - **GBA1 gene mutation**: GBA1 gene mutation is a major genetic risk factor for Parkinson's disease, resulting in a decrease in GCase activity in lysosomes, which in turn affects the lysosome - autophagy process. - **The mechanism of action of Ambroxol**: Ambroxol, as a small - molecule chaperone, can increase the activity of GCase in lysosomes and thus may become a disease - modifying therapy for GBA1 - related and sporadic PD. ### Research methods: - **Cell culture**: Primary cortical neurons were used for the experiment. - **Drug treatment**: Neurons were treated with different concentrations of Ambroxol (10 μM, 30 μM). - **Detection methods**: Cell viability was evaluated by Live/Dead assay, protein levels were detected by Western Blot, mRNA levels were detected by qPCR, and the release of α - synuclein was detected by ELISA. ### Conclusion: The research results show that Ambroxol can not only increase the activity of wild - type GCase and lysosomal contents, but also activate TFEB, affect the autophagy pathway, increase mitochondrial content, and promote the exocytosis of α - synuclein. These findings support the application of Ambroxol as a potential disease - modifying therapy in the treatment of Parkinson's disease.

Effects of ambroxol on the autophagy-lysosome pathway and mitochondria in primary cortical neurons

Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells

Molecular mechanisms of the ambroxol action in Gaucher disease and GBA1 mutation-associated Parkinson disease

The lysosomal β-glucocerebrosidase strikes mitochondria: implications for Parkinson's therapeutics

Neurorestorative effects of sub-chronic administration of ambroxol in rodent model of Parkinson's disease

Study protocol of the GRoningen early-PD Ambroxol treatment (GREAT) trial: a randomized, double-blind, placebo-controlled, single center trial with ambroxol in Parkinson patients with a GBA mutation

Protective Effects of Ambroxol on Aβ and α-Synuclein-Induced Neurotoxicity Through Glucocerebrosidase Activation in HT-22 Hippocampal Neuronal Cells

Clinical and preclinical insights into high-dose ambroxol therapy for Gaucher disease type 2 and 3: A comprehensive systematic review

Parkinson disease-linked GBA mutation effects reversed by molecular chaperones in human cell and fly models

Lysosomal lipid alterations caused by glucocerebrosidase deficiency promote lysosomal dysfunction, chaperone-mediated-autophagy deficiency, and alpha-synuclein pathology

The GBA1 K198E Variant Is Associated with Suppression of Glucocerebrosidase Activity, Autophagy Impairment, Oxidative Stress, Mitochondrial Damage, and Apoptosis in Skin Fibroblasts

Dysregulation of mitochondria-lysosome contacts by GBA1 dysfunction in dopaminergic neuronal models of Parkinson’s disease

Glucocerebrosidase Mutations Cause Mitochondrial and Lysosomal Dysfunction in Parkinson's Disease: Pathogenesis and Therapeutic Implications

Glucocerebrosidase Mutations Cause Mitochondrial and Lysosomal Dysfunction in Parkinson’s Disease: Pathogenesis and Therapeutic Implications

Inhibition of microglial β-glucocerebrosidase hampers the microglia-mediated antioxidant and protective response in neurons

Activation of β-Glucocerebrosidase Reduces Pathological α-Synuclein and Restores Lysosomal Function in Parkinson's Patient Midbrain Neurons

Navigating the cellular pathways: Chaperone-mediated autophagy as a targeted approach for management of parkinson\'s disease

Glucocerebrosidase is imported into mitochondria and preserves complex I integrity and energy metabolism

Dysregulation of the autophagic-lysosomal pathway in Gaucher and Parkinson's disease

Inhibition of neuronal mitochondrial complex I or lysosomal glucocerebrosidase is associated with increased dopamine and serotonin turnover

Exploring the efficacy and safety of Ambroxol in Gaucher disease: an overview of clinical studies